MODERN ALGORITHM OF TREATMENT OF PATIENTS WITH PROSTATE CANCER WITH BONE METASTASES

Authors

  • O.V. Ponomarova Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України, Київ, Україна
  • N.K. Ternovoy Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України, Київ, Україна
  • E.V. Tuz Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України, Київ, Україна
  • N.N. Kolotilov ГУ «Институт ядерной медицины и лучевой диагностики НАМН Украины»
  • V.M. Pivniuk Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України, Київ, Україна
  • V.N. Grigorenko ГУ «Институт урологии НАМН Украины»
  • V.S. Sakalo ГУ «Институт урологии НАМН Украины»
  • P.G. Yakovlev Национальный медицинский университет им. А.А.Богомольца
  • A.V. Sakalo ГУ «Институт урологии НАМН Украины»
  • S.I. Boychuk Национальный институт рака МЗ Украины
  • Т.А. Gobatiuk Киевский городской клинический онкологический центр МЗ Украины
  • N.P. Ogorodnikova Киевский городской клинический онкологический центр МЗ Украины
  • Т.В. Dehtiar Клиника «Борис», Киев, Украина
  • Т.В. Grushinskaya Киевский городской клинический онкологический центр МЗ Украины
  • I.V. Vovchenko Киевский городской клинический онкологический центр МЗ Украины
  • V.E. Cheshuk Национальный медицинский университет им. А.А.Богомольца
  • A.N. Kliusov Киевский городской клинический онкологический центр МЗ Украины

Keywords:

prostate cancer, bone metastases, drug therapy, antiresorptive McAB, bisphosphonate, efficacy, quality of life of patients.

Abstract

Summary. Objective: to substantiate the choice of
therapeutic tactics in patients with bone metastases of
prostate cancer (PC) on the basis of clarifying certain
aspects of the effect of antiresorptive drugs on bone metabolism. Object and methods: 50 patients with PC who
had metastatic bone lesions at different stages of the
disease: 25 patients (group 1) received anti-resorptive
monoclonal antibody therapy, 25 — treatment with
bisphosphonate (group 2). The examination of patients
included clinical, laboratory, instrumental methods in
accordance with modern standards. Results: the total
response to antiresorptive therapy at 12 months of follow-up was 88% in group 1 (of which 76% — positive
dynamics) and 80% in group 2 (positive for 44%) and
the quality of life of patients was improved, the incidence of disabling bone events decreased, and the treatment had a favorable safety profile. The treatment has
a favorable safety profile. When the treatment was effective, the serum content of the N-terminal propeptide procollagen type I (P1NP) and tartrate resistant
acid phosphatase (Bone TRAP-5b) decreased: by the
6–12th month of therapy. With the progression of the
disease in different periods both markers levels are significantly increased. Conclusion: the inclusion of antiresorptive therapy in the treatment algorithm for patients with bone metastases PCa meets the requirements
of efficiency and safety; to monitor such treatment, serum levels of TRAP-5b enzyme and P1NP bone matrix forming marker can be used as markers.

References

Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001; 92: 460–70.

Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260–8.

Connolly JA, Shinohara K, Presti JCJ. Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996; 47: 225–31.

Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev 1996; 17: 308–32.

Yaturu S, DePrisco C, DjoDjo S. Effect of biphosphonates in osteoporosis secondary to LHRH analogs for prostate cancer abstract. J Bone Miner Res 2002; 17: 474.

Демидко ЮЛ, Абутаева БД, Винаров АЗ, Безруков ЕА. Костный обмен при местно-распространенном и диссеминированном раке предстательной железы. Онкоурология 2008; 2: 40.

Huggins C, Hodges СV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7.

Quinn JMW, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophagecolony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998; 139: 4424–7.

Schaffer DL, Pendergrass HP. Comparison of enzyme, clinical, radiographic, and radionuclide method of detecting bone metastases from carcinoma of the prostate. Radiology 1976; 121: 431.

Suda Т, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res 1997; 12: 869–79.

Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305–11.

Charhon SA, Chapuy MC, Delvin EE, et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 1983; 51: 918–24.

Bikle DD. Biochemical markers in the assessment of bone disease. Am J Med 1997; 103: 427–36.

Карякин ОБ, Матвеев БП, Матвеев ВБ и др. Зометав терапии рака предстательной железы с метастатическим

поражением костей на фоне андрогенной депривации (результаты Российского многоцентрового исследования). Онкоурология 2007; (2): 56–60.

Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblast. J Urol 1996; 156: 526–31.

Sells Galvin RJ, Gatlin CL, Horn JW, Fuson TR. TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun 1999; 265A: 233–9.

Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001; 57: 611–6.

Bruder JM, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen deprivation abstract. J Bone Miner Res 2002; 17: 411.

Cecchini MG, Wetterwald A, van der Pluijm G, Thalmann GN. Molecular and biological mechanism of bone metastasis. EAU Update Series 2005; 3: 214– 26.

Persival RC, Urvin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate

is associated with increased bone resorption. Eur J Surg Oncol 1987; 13: 41–9.

Zhang J, Dai J, Yao Z, et al. Soluble receptor activator of nuclear factor кВ Fc diminishes prostate cancer progression in bone. Cancer Res 2003; 63 (22): 7883–90.

Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin/osteoelastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003; 63: 2096–102.

Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis 2010; 13 (1): 20–7.

Cenni E, Perut F, Granchi D, et al. Primitive and bone metastatic renal carcinoma cells promote osteoclastogenesis through endothelial cells. Ant Res 2006; 26: 3065–70.

Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350 (17): 1655–64.

Chirgwin JM, Mohammad KS, Guise KS. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004; 4 (3): 308–18.

Волков НМ. Механизм развития метастазов в кости. Практ онкол 2011; 12 (3): 97–102.

Berenson JR, Rajdev L, Broder M. Pathophysiology of bone metastases. Cancer Biol Ther 2006; 5 (9): 1078–81.

Roodman GD, Dougal WC. RANK ligandas a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008; 34 (1): 92–101.

Downloads

Published

2017-09-20

How to Cite

Ponomarova, O., Ternovoy, N., Tuz, E., Kolotilov, N., Pivniuk, V., Grigorenko, V., Sakalo, V., Yakovlev, P., Sakalo, A., Boychuk, S., Gobatiuk Т., Ogorodnikova, N., Dehtiar Т., Grushinskaya Т., Vovchenko, I., Cheshuk, V., & Kliusov, A. (2017). MODERN ALGORITHM OF TREATMENT OF PATIENTS WITH PROSTATE CANCER WITH BONE METASTASES. Oncology, 19(3), 206–211. Retrieved from https://nasu-periodicals.org.ua/index.php/oncology/article/view/28794

Issue

Vol. 19 No. 3 (2017): Oncology

Section

Original investigations